| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H19Cl3O8 |
| Molecular Weight | 397.633 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl
InChI
InChIKey=BAQAVOSOZGMPRM-QBMZZYIRSA-N
InChI=1S/C12H19Cl3O8/c13-1-4-7(17)10(20)12(3-14,22-4)23-11-9(19)8(18)6(15)5(2-16)21-11/h4-11,16-20H,1-3H2/t4-,5-,6+,7-,8+,9-,10+,11-,12+/m1/s1
Sucralose (sold commercially as Splenda), a water-soluble chlorocarbohydrate, is a sweetener used to sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. In the European Union, it is also known under the E number E955. It is approved in USA by FDA under Chapter I-Food and Drug administration as a multipurpose additive permitted for direct addition to food for human consumption. Splenda is stated to be safe for use by subjects with type 2 diabetes since it does not effect glucose homeostasis in these patients. There is one ongoing clinical trial on effect and safety of sucralose in patients with type 2 diabetes in intensive insulin therapy.
Originator
Approval Year
Sample Use Guides
Expected human daily intake is at a level of 1.1 mg/kg/day. individuals with type 2 diabetes.
Route of Administration:
Oral
To map of the sweet taste enhancer interaction site in sweet–umami chimeric receptors hT1R2-1/hT1R3 and hT1R1-2/rT1R3 stable cell lines were assayed by using fluorescence imaging plate reader (FLIPR). Dose-dependent response curves of hT1R2-1/hT1R3 stable cell line were determined in the absence and presence of SE-2 at sucralose increasing concentration up to 10 mM.
ACTIVE MOIETY
